Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. Export

@article{citeulike:3206115, abstract = {Axonal degeneration has been identified as the major determinant of irreversible neurological disability in patients with multiple sclerosis (MS). Axonal injury begins at disease onset and correlates with the degree of inflammation within lesions, indicating that inflammatory demyelination influences axon pathology during relapsing-remitting MS (RR-MS). This axonal loss remains clinically silent for many years, and irreversible neurological disability develops when a threshold of axonal loss is reached and compensatory CNS resources are exhausted. Experimental support for this view-the axonal hypothesis-is provided by data from various animal models with primary myelin or axonal pathology, and from pathological or magnetic resonance studies on MS patients. In mice with experimental autoimmune encephalomyelitis (EAE), 15-30\% of spinal cord axons can be lost before permanent ambulatory impairment occurs. During secondary progressive MS (SP-MS), chronically demyelinated axons may degenerate due to lack of myelin-derived trophic support. In addition, we hypothesize that reduced trophic support from damaged targets or degeneration of efferent fibers may trigger preprogrammed neurodegenerative mechanisms. The concept of MS as an inflammatory neurodegenerative disease has important clinical implications regarding therapeutic approaches, monitoring of patients, and the development of neuroprotective treatment strategies.}, address = {Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, USA.}, author = {Bjartmar, C. and Wujek, J. R. and Trapp, B. D.}, citeulike-article-id = {3206115}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/12559505}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=12559505}, day = {15}, issn = {0022-510X}, journal = {Journal of the neurological sciences}, keywords = {axonal, clinical, degeneration, ms, therapy}, month = {February}, number = {2}, pages = {165--171}, posted-at = {2008-09-08 13:50:17}, priority = {3}, title = {Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/12559505}, volume = {206}, year = {2003} }

TY - JOUR ID - citeulike:3206115 L3 - citeulike-article-id:3206115 N2 - Axonal degeneration has been identified as the major determinant of irreversible neurological disability in patients with multiple sclerosis (MS). Axonal injury begins at disease onset and correlates with the degree of inflammation within lesions, indicating that inflammatory demyelination influences axon pathology during relapsing-remitting MS (RR-MS). This axonal loss remains clinically silent for many years, and irreversible neurological disability develops when a threshold of axonal loss is reached and compensatory CNS resources are exhausted. Experimental support for this view-the axonal hypothesis-is provided by data from various animal models with primary myelin or axonal pathology, and from pathological or magnetic resonance studies on MS patients. In mice with experimental autoimmune encephalomyelitis (EAE), 15-30% of spinal cord axons can be lost before permanent ambulatory impairment occurs. During secondary progressive MS (SP-MS), chronically demyelinated axons may degenerate due to lack of myelin-derived trophic support. In addition, we hypothesize that reduced trophic support from damaged targets or degeneration of efferent fibers may trigger preprogrammed neurodegenerative mechanisms. The concept of MS as an inflammatory neurodegenerative disease has important clinical implications regarding therapeutic approaches, monitoring of patients, and the development of neuroprotective treatment strategies. IS - 2 JF - Journal of the neurological sciences SN - 0022-510X AD - Department of Neurosciences, Lerner Research Institute, Cleveland Clinic Foundation, 9500 Euclid Ave., Cleveland, OH 44195, USA. EP - 171 TI - Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. VL - 206 SP - 165 KW - axonal KW - clinical KW - degeneration KW - ms KW - therapy AU - Bjartmar, C AU - Wujek, JR AU - Trapp, BD PY - 2003/02/15/ UR - http://view.ncbi.nlm.nih.gov/pubmed/12559505 ER -